Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Jacques F;Melanson M;Kremenchutzky M;Lapierre Y;O'Connor P;Blevins G;Wandinger K;Sommer N;Heesen C;Pozzilli C;GALLO, PAOLO;Comi G;Arbizu T;Fernandez O;Montalban X;Casanova B;Garcia Moreno A;Absher J;Cooper J;Khatri B;Fox E;Wynn D;Picone M;Herbert J;Lynch S;Minagar A;Carter J;Sullivan H;Martin J;Ford C;Phillips T;Kasper L;Dunn J;English J;Steingo B;Edwards K;Honeycutt W;Jacobs A;Kaufman M;Freedman M;Pugh S;Vollmer T;Thomas F;Pirko I;Markowitz C;Rose J;Storey J;Jeffery D;Kahn O;Dickson R;Gottesman M;Miller DE;Reingold SC;Cutter G;Wolinsky J;Freedman MS;Edan G.

2010